Collagen Inducers in Valencia: Types and Limits

In short

An inducer does not occupy space: it stimulates. The volume you see at the end is your own collagen, not product.
The two families with the longest clinical track record are poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA). There are also hybrid products, combining calcium hydroxylapatite with hyaluronic acid.
The effect takes weeks and usually needs several sessions. What you see on the first day is largely the liquid the product is carried in, and it goes.
🔑 They are not reversible. There is no enzyme that undoes an inducer. The only exception is partial: in hybrids the hyaluronic acid component can be broken down, not the other one. It is why patient selection matters more here than with a filler.
The evidence is favourable but of low quality: a 2024 systematic review of facial PLLA concludes literally that the evidence on efficacy and safety is of low quality, and another on CaHA could only carry out a qualitative analysis because of the heterogeneity of the studies.
The adverse effects described are mostly mild — bruising, tenderness, swelling — but the nodule is the one specific to this class and deserves a section of its own.
They are no use for a movement line. That is the territory of botulinum toxin.

A collagen inducer does not fill: it makes your own tissue produce collagen. That is the whole difference, and it explains both its sides. The good one: what improves is your own tissue, and the result is built gradually rather than appearing all at once. The uncomfortable one: there is no way back. There is no enzyme that undoes it, as there is with hyaluronic acid.

This page explains what they are, which ones are used, what the evidence says — less solid than the marketing suggests — and when they are not the answer.

If what you want is to restore a specific volume, the standard is hyaluronic acid. If what you want is skin quality, compare it with polynucleotides.

What exactly a collagen inducer is

A filler works by occupancy: a gel is placed where volume is missing and that gel supports the area for as long as it is there. It shows the same day, and it goes when the product breaks down.

An inducer works by reaction. A material is injected that the body recognises as foreign and gradually reabsorbs, and that controlled reabsorption stimulates the fibroblasts to produce collagen. The product disappears; the collagen stays. Hence the three practical consequences that order everything else:

It is not immediate. Biological time is needed. What you see in the consulting room afterwards is usually the vehicle — water or gel — and it disappears within days.
It is not a volume you can draw. It is an improvement in the thickness and firmness of an area, not the millimetre correction of a fold.
It cannot be removed. If the result is not liked or a late nodule appears, the approach is not to dissolve it: it is to treat whatever has appeared. The only exception is partial and is explained below, with hybrid products.

The two that are used

	Poly-L-lactic acid (PLLA)	Calcium hydroxylapatite (CaHA)
What it is	A resorbable polymer, the same material as surgical sutures	Microspheres of a bone mineral in a carboxymethylcellulose gel
How it acts	Pure stimulation: practically all the effect is new collagen	Double: the gel gives immediate volume and the microspheres stimulate afterwards
Initial effect	Slight and temporary	Yes, visible the same day, from the gel
Pace	Gradual, usually several sessions weeks apart	Faster in the filling component; the stimulation is gradual
Where it has most backing	Diffuse loss of volume and facial lipoatrophy	Cheeks, jawline, nasolabial folds, HIV-associated facial lipoatrophy
Reversible	No	No

Both share the essential point: they are used when the problem is a global loss of support and quality, not one specific point.

The third family: hybrids

There are also products combining calcium hydroxylapatite with hyaluronic acid in the same syringe. The idea is to cover both at once: the hyaluronic acid gives volume from day one, and the hydroxylapatite stimulates collagen afterwards. For a patient who wants to see something soon and also build over the medium term, it is an attractive proposition.

But there is a caveat worth understanding beforehand, and it is the one that links to everything above: a hybrid is only half reversible. If the result is not convincing or a problem arises, hyaluronidase can break down the hyaluronic acid component — the immediate volume — but it does not touch the hydroxylapatite. What is undone is part of what was put in, not the treatment.

It is not a drawback that rules anything out. It is information to have before signing, because “it contains hyaluronic acid, so it can be removed” is a reasonable and mistaken conclusion.

What the evidence actually says

Here it is worth lowering the advertising tone, because the distance between what is promised and what is published is considerable.

On PLLA. A 2024 systematic review gathered eleven randomised clinical trials from 1,467 references. Four described an increase in dermal thickness and significant improvement in facial lipoatrophy and on aesthetic scales, with effects maintained for more than 25 months. Adverse effects were mild to moderate in intensity: bruising, tenderness, nodules and swelling. But five studies had a high risk of bias, and the authors conclude that the evidence on the efficacy and safety of PLLA in facial rejuvenation is of low quality. Another review from the same year, with twenty studies — only four of them randomised — sums it up as a material that is “reasonably safe and effective”, with adverse effects mostly mild and self-limiting.

On CaHA. A 2024 systematic review of controlled trials started from 2,935 references and kept thirteen studies: eight facial and five of the back of the hand. The heterogeneity was such that only a qualitative analysis could be carried out. The direction is favourable — improvement on global scales and high patient satisfaction — but the authors themselves point out the methodological limitations.

🔑 And one fact almost nobody publishes. The 2024 review of CaHA with carboxymethylcellulose distinguishes clearly between what is in the product information — filling lines, adding volume and contouring — and what is used off-label: biostimulation and skin tightening. And it adds that, despite the fashion for diluted and hyperdiluted product for skin quality, no randomised trial has been published supporting it. That does not mean it does not work; it means anyone offering it to you as a proven technique is telling you something the literature does not yet support.

When they make sense and when they do not

They fit well when the problem is diffuse: skin that has lost thickness and firmness, a general loss of support in the middle third, lipoatrophy. That is, when the complaint is “I look dull and I am sagging” rather than “I am missing volume here”.

They are not the answer in these cases:

A movement line — frown lines, crow’s feet, forehead lines. That depends on muscle contraction and is addressed with botulinum toxin, not with collagen.
A specific defect that has to be corrected precisely. A particular fold, defining a lip outline: that is filler.
Where being able to change your mind matters. If it is your first treatment, if you have doubts or if you are going for a visible change, starting with something reversible is good sense, not timidity.
Where what is in excess is skin. No injectable replaces surgery when the problem is excess skin. An inducer improves the quality of the tissue; it does not remove it.
Over an active infection in the area, or with a history of reactions to implants.

Risks and what to watch for

The frequent adverse effects are those of any injection: bruising, swelling, tenderness, redness. They resolve on their own.

The risk specific to this class is the nodule: a palpable lump that can appear weeks or months later. It appears in the PLLA series and in the CaHA series too, and it is what makes correct technique, the right plane and — with PLLA — reconstitution and massage according to protocol so important.

A 2025 systematic review of combining biostimulators with toxin, fillers and devices gathered 29 studies and described adverse effects in 15–30% of cases — erythema, bruising, nodules — with serious complications rare. It is a high figure that needs reading properly: it includes the mild and temporary, and it comes from very heterogeneous studies.

⚠️ And a warning about how to read all this. A 2025 review of adverse effects of toxin and fillers says it plainly: there is a publication bias in favour of favourable results over adverse effects. When a technique appears to have no drawbacks, what is often missing is the record, not the problem.

As with any facial injectable, there is also a vascular risk. It is uncommon and is described on the vascular occlusion page, with one important difference: if the material is not hyaluronic acid, it cannot be dissolved.

Book an appointment

You can book your own appointment. Pick the day and time from the free slots in the diary, in a panel that opens right here, without leaving this page.

Book an appointment

Frequently asked questions

How long does the result take to show?

Weeks, not days. What you see as you leave is largely the liquid the product is carried in and it disappears. The real effect builds as collagen is produced, which is why several sessions spaced over time are usually planned.

How long does it last?

In the PLLA systematic review, the studies that measured duration described effects maintained for more than 25 months. That is an aggregate figure, not an individual promise: it depends on the product, the amount, the area and each person’s biology.

Can it be removed if I do not like it?

No. It is the fundamental difference from hyaluronic acid, which can be broken down with hyaluronidase. With an inducer there is no antidote: if a nodule appears it is treated, but the treatment is not dissolved. With a hybrid product the hyaluronic acid component can be broken down, but not the other: the reversibility is partial, not complete.

Is it the same as a filler?

No. A filler occupies a space and supports volume for as long as it is there; an inducer triggers a response from the tissue and what remains is your own collagen. They are used for different things and are sometimes combined.

Does it work for frown lines or crow’s feet?

No. Those lines depend on muscle movement. The comparison between the two situations is in botulinum toxin or hyaluronic acid.

Are polynucleotides collagen inducers?

They are often grouped with them because they share the idea of stimulating the tissue rather than filling it, but they are not the same: polynucleotides work on the quality of the skin — hydration, elasticity, fine lines — and do not aim for the structural effect of a PLLA or a CaHA. They have their own page, with one important difference: the published evidence on them is far thinner.

And for skin quality?

It is used for that purpose, but outside the product’s licensed indications and, in the case of the diluted product, with no published randomised trials. If the main aim is skin quality, it is worth comparing with facial redensification and with polynucleotides before deciding.

Does it hurt?

It is an injection: it is uncomfortable. Topical anaesthetic is used and some products include a local anaesthetic. The most common experience afterwards is the area feeling tender for a few days.

Can it be combined with other treatments?

It is done, and there is literature exploring it. The 2025 review of combinations concludes that the results point to improvements in texture and contour, but that heterogeneous methods and small samples limit reliability. Combining as a matter of routine, without a reason for each element, is not supported.

Sources

Signori R, Barbosa AP, Cezar-Dos-Santos F, et al. Efficacy and Safety of Poly-l-Lactic Acid in Facial Aesthetics: A Systematic Review. Polymers (Basel). 2024;16(18). Eleven randomised trials from 1,467 references; four studies describe increased dermal thickness and improvement in facial lipoatrophy with effects beyond 25 months; mild-to-moderate adverse effects (bruising, tenderness, nodules, swelling); five studies at high risk of bias; the authors conclude that the evidence is of low quality. https://pubmed.ncbi.nlm.nih.gov/39339028/
Xu Q, Sun X, Yang W, Bai Y, Tan X. Comprehensive Systematic Review of Poly-L-lactic Acid in Facial Clinical Application. Aesthetic Plast Surg. 2024;48(23). Twenty studies included, of which only four are randomised trials; most adverse effects are mild and self-limiting. https://pubmed.ncbi.nlm.nih.gov/38902341/
Amiri M, Meçani R, Llanaj E, et al. Calcium Hydroxylapatite (CaHA) and Aesthetic Outcomes: A Systematic Review of Controlled Clinical Trials. J Clin Med. 2024;13(6). Thirteen studies from 2,935 references, eight facial and five of the back of the hand; only a qualitative analysis was possible because of the high heterogeneity; improvement on global scales and high satisfaction, with acknowledged methodological limitations. https://pubmed.ncbi.nlm.nih.gov/38541911/
Guida S, Galadari H. A systematic review of Radiesse/calcium hydroxylapatite and carboxymethylcellulose: evidence and recommendations for treatment of the face. Int J Dermatol. 2024;63(2). It distinguishes the licensed indications — filling lines, adding volume and contouring — from off-label uses — biostimulation and tightening; it considers the product safe and effective in the cheeks, jawline, HIV-associated facial lipoatrophy and nasolabial folds; and it notes that no randomised trials have been published on the diluted and hyperdiluted product. https://pubmed.ncbi.nlm.nih.gov/37897174/
Tam E, Choo JPS, Rao P, Webb WR, Carruthers JDA, Rahman E. A Systematic Review on the Effectiveness and Safety of Combining Biostimulators with Botulinum Toxin, Dermal Fillers, and Energy-Based Devices. Aesthetic Plast Surg. 2025;49(10). Twenty-nine studies out of 1,237 identified, with samples of 10 to 350 subjects; adverse effects in 15–30% of cases (erythema, bruising, nodules) and serious complications rare; heterogeneous methods and inconsistent protocols limit reliability. https://pubmed.ncbi.nlm.nih.gov/39719485/
Di Santis ÉP, Hirata SH, Di Santis GM, Yarak S. Adverse effects of the aesthetic use of botulinum toxin and dermal fillers on the face: a narrative review. An Bras Dermatol. 2025;100(1). It notes a publication bias in favour of successful results over adverse effects and calls for mandatory reporting of the latter. https://pubmed.ncbi.nlm.nih.gov/39616095/

Book your consultation

The useful question is not “should I have an inducer?”, but “is what is happening to me solved by stimulating collagen, restoring volume, relaxing a muscle or removing skin?”. They are four different problems and only one is solved here.

At the assessment we examine the face at rest and in movement, identify what weighs most in your case and also tell you when the answer is not to treat, or to treat something else. And if the option is an inducer, you are told beforehand what this page has already told you: that there is no way back.